Therapeutic Efficacy of Quinapyramine Sulphate with Freund’s Complete Adjuvant in Wistar Rats Infected with Trypanosoma Congolense

Abstract

Therapeutic efficacy of QS (quinapyramine sulphate) and FCA (Freund’s complete adjuvant) combination was studied. The aim of the study was to evaluate therapeutic efficacy of QS using FCA in Trypanosoma congolense infection. Groups treated with QS and FCA had parasite disappeared in peripheral circulation 2 days pi, relapse was observed one week later. Effect of treatment on rectal temperature shows no significance (p < 0.05), normalization of rectal temperature occurred in QS and FCA treated groups (34.1 ℃) than untreated (42.8 ℃), QS (37.4 ℃) and FCA (35.92 ℃) treated groups. Mean body weight was significant (p < 0.001) in QS and FCA, QS, and FCA groups. Packed cell volume and hemoglobin concentration for untreated groups were lower, but increased in QS, FCA, QS and FCA treated groups, indicating anemia amelioration. White blood cell counted in untreated, QS and FCA treated groups showed no significance (p < 0.05), however, there was leukocytosis due to lymphocytosis in QS and FCA treated group (6.79 × 103/μl) compared with untreated and other groups. There was comparative decrease in serum liver enzymes in QS and FCA treated group than other groups. Therefore, QS at lower recommended dose with FCA may enhance efficacy of QS in trypanosomiasis.